TB-500 is a 17-amino-acid fragment of Thymosin Beta-4 containing the primary actin-binding sequence. Full Tβ4 has additional activities TB-500 lacks, including cardiac progenitor cell activation. Read the TB-500 page →
COMPOUND PROFILE · PEPPERLEDGER
Thymosin Beta-4 (Tβ4)
Endogenous protein — naturally present in virtually all mammalian cells · RegeneRx Biopharmaceuticals (clinical development)
Type
Endogenous 43-amino-acid actin-sequestering protein — one of the most abundant intracellular peptides in the body
Subcutaneous injection · IV (used in clinical trials) · Eye drops (RGN-259 — ophthalmic formulation in Phase III)
Half-life
Short plasma half-life — rapidly distributed to tissues
Most studied use
Cardiac repair after MI · Corneal healing and dry eye · Wound healing · Musculoskeletal repair
Regulatory status
Not FDA-approved as systemic therapy · Phase II cardiac trials completed · RGN-259 eye drop formulation in Phase III for dry eye and neurotrophic keratopathy · WADA-banned
Human evidence
Moderate — Phase II cardiac repair data; Phase II/III ophthalmic data (corneal healing and dry eye); human safety established
Preclinical evidence
Exceptional — 50+ years of research; landmark Nature papers on cardiac progenitor cell activation
EDUCATIONAL TOOL — NOT MEDICAL ADVICE
Full Tβ4 vs. TB-500 — the actual difference
Every cell in the human body contains Thymosin Beta-4 in high concentrations — it is one of the most abundant intracellular peptides in mammalian cells. Its primary function is actin sequestration: binding G-actin (monomeric actin) to regulate the pool available for polymerization, governing cell shape, migration, and division. TB-500 was created as a practical injectable form of the active region of Tβ4 — the 17-amino-acid LKKTETQ fragment that retains the actin-binding and cell migration properties.
Full-length Tβ4 has additional biological activities beyond the TB-500 fragment. Most critically: cardiac progenitor cell activation, demonstrated in landmark Nature papers where Tβ4 reactivated dormant epicardial cells after myocardial infarction, causing them to differentiate into cardiomyocytes and vascular smooth muscle. This mechanism is specific to the full-length protein's interaction with integrin-linked kinase (ILK) — TB-500 does not fully replicate it.
Practical choice: for most tissue repair and injury recovery, TB-500 is the pragmatic option with more accumulated community data. Full Tβ4 is the choice when specifically targeting the cardiac repair mechanism, or wanting the complete biological profile of the natural protein.
How it works
Actin Sequestration — Shared with TB-500
Full Tβ4 contains the same LKKTETQ actin-binding sequence that TB-500 is derived from. It sequesters G-actin, regulating cytoskeleton dynamics that govern cell migration, shape, and division. Wound healing, tissue repair, and angiogenic mechanisms are shared between the full protein and the TB-500 fragment.
Cardiac Progenitor Cell Activation — Unique to Full Tβ4
The 2007 Smart et al. Naturepaper demonstrated that Tβ4 activates dormant cardiac progenitor cells (epicardial cells) after myocardial infarction — causing differentiation into cardiomyocytes and vascular smooth muscle cells. This cardiac regeneration mechanism is specific to the full-length protein's interaction with integrin-linked kinase (ILK), not captured by the TB-500 fragment. This is the biological basis for Tβ4's cardiac repair clinical development.
Ophthalmic Effects
Tβ4 promotes corneal epithelial cell migration, angiogenesis in the limbal vasculature, and anti-inflammatory effects on the ocular surface. Eye drops deliver Tβ4 directly to corneal tissue without systemic exposure — the most clinically advanced pathway, with Phase III data for dry eye and neurotrophic keratopathy (RGN-259).
Anti-Inflammatory and Immunomodulatory
Full Tβ4 has broader anti-inflammatory effects than TB-500 — NF-κB suppression, TNF-α reduction, and modulation of dendritic cell function. The full protein's immunomodulatory profile is more complete than the fragment.
What the research shows
STUDYNature · 2007
Thymosin beta-4 induces adult epicardial progenitor mobilization and neovascularization
Smart N et al.
Landmark paper. Tβ4 reactivates dormant epicardial progenitor cells after MI in mice, producing cardiomyocyte and vascular smooth muscle differentiation. Led directly to cardiac repair clinical development. Establishes the unique cardiac mechanism of full Tβ4 vs. TB-500.
Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair
Bock-Marquette I et al.
Second landmark Nature paper. Tβ4 promotes cardiac cell survival and repair via ILK signaling — the mechanism TB-500 does not fully replicate. Establishes the molecular basis for the full protein's cardiac-specific activities and the distinction from the fragment.
RGN-259 (Tβ4 Eye Drops) for Dry Eye and Neurotrophic Keratopathy — Phase II/III
Sosne G et al.
Phase II/III data for Tβ4 eye drops. Significant improvements in corneal staining, symptom scores, and healing of corneal defects. The most clinically advanced Tβ4 application — the pathway most likely to produce the first Tβ4-based FDA approval.
Full Tβ4 is less commonly used in biohacker communities than TB-500 — partly expense and availability, partly more accumulated protocol data for the fragment. Users who specifically seek full Tβ4 are typically those who have researched the cardiac progenitor cell activation literature and want the additional biological activities. General tissue repair reports are similar to TB-500. Post-cardiovascular event use is a specific community application — some users target full Tβ4 rather than TB-500 specifically for the cardiac mechanism.
WHAT THE RESEARCH SHOWS
✓KNOWN
✓Cardiac progenitor cell activation confirmed in landmark Nature animal studies — unique to full Tβ4 vs. TB-500
✓Corneal healing in Phase II/III ophthalmic trials (RGN-259) — most clinically advanced Tβ4 application
✓Human safety established across multiple clinical trials (cardiac Phase II and ophthalmic Phase II/III)
✓Broader anti-inflammatory profile than TB-500 — NF-κB suppression, TNF-α reduction
✓WADA-banned in and out of competition
?UNCERTAIN
?Whether cardiac progenitor cell activation translates to meaningful human cardiac repair outcomes — Phase II trend, no Phase III
?Whether full Tβ4 is meaningfully superior to TB-500 for musculoskeletal tissue repair in humans
?Optimal systemic dosing for tissue repair — extrapolated from TB-500 community protocols
?Long-term systemic safety beyond trial durations
RECONSTITUTION CALCULATOR
EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN
AI COACH PREVIEW
What's the practical difference between full Thymosin Beta-4 vs. TB-500 for my rotator cuff recovery? Which should I use?
For rotator cuff recovery specifically, TB-500 is the practical choice. The additional activities of full Tβ4 — cardiac progenitor cell activation, broader immunomodulatory effects — are not what you're optimizing for with a shoulder injury. TB-500 retains the LKKTETQ actin-binding sequence driving cell migration, tissue repair, and anti-inflammatory effects in musculoskeletal tissue. It has more community protocol data, is more accessible and generally less expensive, and produces equivalent outcomes for the tissue repair application. Full Tβ4 makes more sense when: you specifically want the cardiac mechanism (post-MI or cardiac recovery), you want the complete immunomodulatory profile alongside tissue repair, or the ophthalmic application applies to you. Protocol for rotator cuff: 2 mg SC twice weekly for 4 weeks loading, then 2 mg once weekly for 4–8 weeks maintenance (same whether full Tβ4 or TB-500). Strongly consider stacking with BPC-157 (250 mcg SC daily) — BPC-157 promotes growth factor recruitment and angiogenesis; Tβ4/TB-500 drives cell migration into the injury. They're complementary for structural injury recovery and this is one of the most commonly reported effective combinations in the community.
CONTINUE IN THE APP
Open PepperLedger to track your Tβ4 protocol →
Free to join. The Coach understands the Tβ4 vs. TB-500 distinction and can help structure the right protocol for your goals.
Free to join · No credit card · 23-day Pro trial included